Rapid and Simultaneous Initiation of Four Guideline-Directed CKD Therapies (RAPID-CKD)

Trial statusNot yet recruiting
Trial phasePhase 4
Trial typeInterventional
Biological sexAll
Age18-84
SponsorBaylor Research Institute

About this trial

The goal of this clinical trial is to learn if starting four kidney disease medicines quickly and together (a rapid treatment approach) is safe and works well in people with type 2 diabetes and chronic kidney disease.

The main questions it aims to answer are:

* Is it safe to start these medicines over a short period of time? * How often do kidney function changes or high potassium levels occur? * Does this approach lower protein in the urine (a sign of kidney damage)? * How many participants are able to stay on all four medicines over 6 months?

Researchers will compare this approach to usual care, where medicines are started one at a time over several months.

Participants will:

Be assigned by chance to either this approach or usual care Start up to four approved kidney medicines over about 8 weeks (rapid treatment approach) or follow standard care Have regular clinic visits and lab tests to check kidney function and potassium levels Be followed for about 6 months

Eligibility criteria

Qualifiers

Patients aged 18-84 years

eGFR 45 to ≤90 mL/min/1.73 m2

UACR >200 mg/g

diagnosis of T2D

Disqualifiers

Type 1 diabetes

any known primary non-diabetic kidney disease (i.e., polycystic kidney disease, glomerulonephritis, interstitial nephritis, etc.)

history of kidney transplant

liver disease (i.e., aspartate transaminase or alanine transaminase >5 times, or bilirubin >3 times the upper limit of normal)

Trial design

Treatments tested in this trial

  • Finerenone
  • Semaglutide
  • Lotensin
  • Capoten
  • Enalapril
  • Monopril
  • Lisinopril
  • Univasc
  • Aceon
  • Accupril
  • Altace
  • Mavik
  • Edarbi
  • Atacand
  • Avapro
  • Cozaar
  • Benicar
  • Micardis
  • Diovan
  • Invokana
  • Farxiga
  • Jardiance
  • Ertugliflozin
  • Brenzavvy
  • Sotagliflozin

Treatment groups

64 Participants
are divided into 2 treatment groups

Sponsors and collaborators